BTS 71321
Latest Information Update: 26 Nov 2004
At a glance
- Originator Boots Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Skin disorders
Most Recent Events
- 31 Dec 2002 Discontinued - Phase-II for Asthma in United Kingdom (PO)
- 31 Dec 2002 Discontinued - Preclinical for Skin disorders in United Kingdom (Topical)
- 29 Oct 1999 BTS 71321 is available for licensing